Alto Neuroscience, Inc. (ANRO)
Official siteHEALTHCARE • BIOTECHNOLOGY • NYSE
Market Cap: $1.18B
Last updated: Nov 17, 2026 at 11:04 AM ET
Alto Neuroscience, Inc. (ANRO) Earnings: Report Dates and Results
In the quarter ended Sep 30, 2026, Alto Neuroscience reported EPS of -$0.54, above the -$0.60 estimate. It beat the EPS estimate in 6 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
ANRO's report for the quarter ending Dec 31, 2026 is not on the earnings calendar yet.
Earnings History
Of the 12 quarters below that had an estimate, ANRO beat 8 and missed 4. The widest gap in the table came in the quarter ended Dec 31, 2023, when EPS landed 365.27% below the estimate.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported |
|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.54 | -$0.60 | -$0.89 - -$0.60 | +10.00% | Beat | N/A | 7 | 0 up, 1 down | Nov 10, 2026 |
| Jun 30, 2026 | -$0.65 | -$0.71 | -$0.96 - -$0.57 | +8.45% | Beat | N/A | 6 | 0 up, 1 down | Aug 12, 2026 |
| Mar 31, 2026 | -$0.80 | -$0.50 | -$0.53 - -$0.48 | -60.00% | Miss | N/A | 2 | 0 up, 0 down | May 13, 2026 |
| Dec 31, 2025 | -$0.45 | -$0.66 | N/A | +31.82% | Beat | N/A | 1 | 0 up, 0 down | Mar 16, 2026 |
| Sep 30, 2025 | -$0.52 | -$0.64 | -$0.64 - -$0.64 | +18.75% | Beat | N/A | 1 | 0 up, 0 down | Nov 12, 2025 |
| Jun 30, 2025 | -$0.65 | -$0.60 | N/A | -8.33% | Miss | N/A | N/A | 0 up, 0 down | Aug 13, 2025 |
| Mar 31, 2025 | -$0.56 | -$0.62 | N/A | +9.68% | Beat | N/A | N/A | 0 up, 0 down | May 14, 2025 |
| Dec 31, 2024 | -$0.52 | -$0.55 | N/A | +5.45% | Beat | N/A | N/A | 0 up, 0 down | Mar 20, 2025 |
| Sep 30, 2024 | -$0.62 | -$0.64 | -$0.76 - -$0.50 | +3.13% | Beat | N/A | 6 | 0 up, 0 down | Nov 12, 2024 |
| Jun 30, 2024 | -$0.60 | -$0.67 | N/A | +10.45% | Beat | N/A | N/A | N/A | Aug 13, 2024 |
| Mar 31, 2024 | -$0.76 | -$0.46 | N/A | -65.22% | Miss | N/A | N/A | N/A | May 14, 2024 |
| Dec 31, 2023 | -$7.77 | -$1.67 | N/A | -365.27% | Miss | N/A | N/A | N/A | Feb 5, 2024 |
Annual EPS
| Fiscal year ended | EPS | Change |
|---|---|---|
| Sep 30, 2026 | -$2.44 | N/A |
| Jun 30, 2026 | -$1.90 | N/A |
| Sep 30, 2025 | -$2.25 | N/A |
| Sep 30, 2024 | -$9.75 | N/A |
Frequently Asked Questions About ANRO
Did ANRO beat earnings estimates last quarter?
Yes. Alto Neuroscience reported EPS of -$0.54 for the quarter ended Sep 30, 2026, above the -$0.60 estimate, a 10.00% surprise.
What EPS do analysts expect from ANRO next quarter?
The consensus EPS estimate for Alto Neuroscience for the quarter ending Dec 31, 2026 is -$0.65 from 13 analysts, with estimates from -$0.78 to -$0.54.
How often does ANRO beat earnings estimates?
Alto Neuroscience beat the EPS estimate in 6 of the last 8 quarters, with an average surprise of +1.98%.
ANRO pages: Overview, Earnings, Forecast, Financials, Competitors